Evidence map›Paper›PMID 35551625›Full record

ArticleEndocrine pathology2022

Clinical-Pathological Evaluation and Prognostic Analysis of 228 Merkel Cell Carcinomas Focusing on Tumor-Infiltrating Lymphocytes, MCPYV Infection and ALK Expression.

Federica Santoro, Francesca Maletta, Renato Parente, Jessica Fissore, Cristian Tampieri, Leonardo Santoro, Nadia Birocco, Franco Picciotto, Pietro Quaglino, Marco Volante and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Endocrine pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 2 countries.

Federica SantoroPathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Francesca MalettaPathology Unit, Department of Laboratory Medicine, Città Della Salute e Della Scienza of Turin, Turin, Italy.
Renato ParentePathology Unit, Humanitas-Gradenigo Hospital, Turin, Italy.
Jessica FissorePathology Unit, Department of Oncology, Città Della Salute e Della Scienza of Turin, University of Turin, Via Santena 7, 10126, Turin, Italy.
Cristian TampieriPathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
Leonardo SantoroInstitute of Mathematics (EPFL), Lausanne, Switzerland.
Nadia BiroccoOncology Unit, Città della Salute e della Scienza, Turin, Italy.
Franco PicciottoDermatologic Surgery Section, Department of Surgery, Città Della Salute e Della Scienza of Turin, Turin, Italy.
Pietro QuaglinoDermatology Clinic, Department of Medical Sciences, Città Della Salute e Della Scienza of Turin, University of Turin, Turin, Italy.
Marco VolantePathology Unit, Department of Oncology, San Luigi Hospital of Orbassano, University of Turin, Turin, Italy.
Sofia AsioliPathology Unit, Department of Biomedical and Neuromotor Sciences (DIBINEM), University of Bologna, Bologna, Italy.
Rebecca Senetta *Pathology Unit, Department of Oncology, Città Della Salute e Della Scienza of Turin, University of Turin, Via Santena 7, 10126, Turin, Italy. rebecca.senetta@unito.it.
Mauro Papotti *Pathology Unit, Department of Oncology, Città Della Salute e Della Scienza of Turin, University of Turin, Via Santena 7, 10126, Turin, Italy.
University of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITÉcole Polytechnique Fédérale de Lausanne · CHOspedale Humanitas Gradenigo · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Merkel cell carcinoma is a rare and aggressive primary neuroendocrine carcinoma of the skin, whose pathogenesis can be traced back to UV radiation damage or Merkel cell polyomavirus (MCPyV) infection. Despite some improvements on the characterization of the disease partly due to its increased incidence, crucial pathogenetic and prognostic factors still need to be refined. A consecutive series of 228 MCC from three hospitals in Turin was collected with the aim of both analyzing the apparent increase in MCC incidence in our area and investigating the distribution and prognostic role of clinical-pathological parameters, with a focus on MCPyV status, ALK tumor expression and tumor infiltrating lymphocytes (TILs). Review of morphology and conventional immunohistochemical staining was possible in 191 cases. In 50 cases, the expression of the novel neuroendocrine marker INSM1 was additionally assessed. Fourteen cases of MCC of unknown primary skin lesion were identified and separately analyzed. While confirming an exponential trend in MCC incidence in the last decades and providing a description of histological and cytological features of a large series of MCC, the present study concludes that 1) INSM1 is a highly sensitive marker in both skin and lymph node primary MCC; 2) positive MCPyV status, brisk TILs and lower tumor size and thickness are independent positive prognostic parameters, and the combination of the former two may provide a novel tool for prognostic stratification; 3) ALK is expressed 87% of MCC and associated with positive viral status, and could represent a prognostic biomarker, if validated in larger series.

Indexed as

Carcinoma, Merkel CellMerkel cell polyomavirusPolyomavirus InfectionsSkin NeoplasmsHumansLymphocytes, Tumor-InfiltratingPrognosisReceptor Protein-Tyrosine KinasesRepressor ProteinsINSM1 protein, humanReceptor Protein-Tyrosine KinasesRepressor ProteinsALK expressionINSM1 expressionMerkel cell carcinomaMerkel cell polyomavirusTumor-infiltrating lymphocytes

Identifiers

PMID35551625
PMCPMC9135831
OpenAlexW4280554423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.